Different Doses of Nebulized Magnesium Sulphate in Status Asthmaticus
Status:
Not yet recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
In this study investigators will use magnesium sulphate in the nebulized form in children
between 2 and 12 years of age as an acute reliever for acute severe asthma. Aim of this study
is to determine that whether adding low (250mg), intermediate (500mg), and high doses (750mg)
of magnesium sulphate in the 1st hour of treatment has any difference in the improvement of
clinical condition of the patient and length of hospital stay. There will be total 108
patients having 2 groups. 1st group will receive only Ventolin while 2nd group will be given
Ventolin and Magnesium sulphate.